Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
A pre-scheduled independent Safety Monitoring Committee (SMC) has recommended that the U.S. Phase 2 COVID-19 study with opaganib continue with no changes; the study is more than 50% enrolled and enrollment is planned to be completed in the coming weeks -- The global Phase 2/3 COVID-19 study with ...
View HTML
Toggle Summary RedHill Biopharma Provides Q2/2020 Financial Results and Operational Highlights
Q2 / 2020 net revenues of approximately $21 million , up from $1.1 million in Q1/2020 and $1.6 million in Q2/2019, an increase of approximately 1,900% and 1,200%, respectively -- Completed acquisition of Movantik ® from AstraZeneca and secured exclusive control over U.S. ...
View HTML
Toggle Summary RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. ...
View HTML
Toggle Summary RedHill Biopharma to Host Second Quarter Financial Results and Business Highlights Conference Call and Webcast on August 13, 2020
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its second quarter 2020 financial results and business highlights on Thursday, ...
View HTML
Toggle Summary RedHill Biopharma’s Phase 2/3 COVID-19 Study Approved in Mexico
The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe  COVID-19 across 40 clinical sites -- The global Phase 2/3 study has been approved in Mexico , the UK and Russia   and is also under review in Italy, Brazil and additional countries -- Enrollment in a parallel ...
View HTML
Toggle Summary RedHill Biopharma to Participate in Upcoming BTIG and Intellisight Conferences
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will participate in the following virtual conferences in August: BTIG Virtual Biotechnology ...
View HTML
Toggle Summary RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik®
RedHill acquired Movantik ® for opioid induced constipation from AstraZeneca in April 2020 ; Movantik ® generated $96 million in 2019 -- RedHill and Daiichi Sankyo replaced their co-commercialization agreement for Movantik ® with a new royalty-bearing agreement, under which RedHill will maintain ...
View HTML
Toggle Summary RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
RHB-204 is a potential first-line oral treatment for pulmonary nontuberculous mycobacteria (NTM) infections, a rare disease with no FDA-approved first-line therapy -- The pivotal Phase 3 study aims to enroll 125 patients at 50 clinical sites across the U.S. ...
View HTML
Toggle Summary RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19
The global Phase 2/3 study will enroll up to 270 patients with severe COVID-19 across 40 clinical sites; The study has been approved in the UK and Russia and is under review in Italy , Brazil and Mexico -- Enrollment in a parallel U.S. Phase 2 study in patients with severe COVID-19 is expected to ...
View HTML
Toggle Summary RedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology
Publication of the Phase 2 U.S. study data show that RHB-102 (Bekinda ® ) 12mg delivers a clinically meaningful improvement in overall stool consistency response versus placebo in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), meeting the study’s primary endpoint -- In ...
View HTML